DARA RVD For High Risk SMM
DARA RVD For High Risk SMM
Active, not recruiting · NCT04775550 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DARA RVD For High Risk SMM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-07-02 | NCT04775550 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Pharmaceuticals | 24 |
| Omar Nadeem, MD | 3 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana-Farber Brigham Cancer Center | South Weymouth | United States | 1 |
| Dana-Farber Brigham Cancer Center - Foxborough | Foxborough | United States | 5 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Dana-Farber Cancer Institute - Merrimack Valley | Methuen | United States | 3 |
| Stamford Hospital | Stamford | United States | 7 |